tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

3 Stocks to Sell Now, According to Top-Rated Analysts – November 3, 2025

Story Highlights

According to the following top-rated Wall Street analysts, the stocks listed below are worth selling, as they are expected to fall from current levels.

3 Stocks to Sell Now, According to Top-Rated Analysts – November 3, 2025

Wondering which stocks to sell right now? According to the following top-rated Wall Street analysts, the stocks listed below are worth selling, as they are expected to fall from current levels. Click on any ticker to thoroughly research the stock before you decide to take any action.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

First Solar (FSLR) Stock – First Solar builds and sells solar panels and develops large-scale solar energy projects. Analyst Sophie Karp from KeyBanc reiterated her Sell rating on the stock and kept the price target at $150 per share. This equates to a downside of more than 43% from current levels. What’s interesting is that analysts overall have a Strong Buy consensus rating on the FSLR stock. However, it is worth noting that Karp has a 69% success rate when it comes to FSLR, with an average return of 16.7% per rating.

Werner Enterprises (WERN) Stock – Werner is a transportation and logistics company that provides truckload shipping and freight management services across North America. Analyst Jonathan Chappell from Evercore ISI reiterated his Sell rating on the stock and cut the price target from $23 to $20 per share. This equates to a downside of more than 23% from current levels. Overall, analysts have a Moderate Sell consensus rating on the stock. Furthermore, Chappell has achieved a 67% success rate with his WERN ratings.

Bristol Myers Squibb (BMY) Stock – Bristol Myers Squibb is a global biopharmaceutical company focused on developing and selling prescription drugs for cancer, heart disease, and immune disorders. Analyst Terence Flynn from Morgan Stanley reiterated his Sell rating on the stock while assigning a $36 per share price target. This equates to a downside of more than 21% from current levels. Interestingly, Flynn is currently the only analyst with a Sell rating on BMY stock. Nevertheless, he has an 80% success rate on the drugmaker with an average return of almost 9% per rating.

To see the full list of recently rated stocks, visit TipRanks’ Daily Stock Ratings & Price Targets tool.

Disclaimer & DisclosureReport an Issue

1